PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
Please provide your email address to receive an email when new articles are posted on . PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Patients who received the newly approved PanOptix trifocal lens reported high levels of ...
Patients now have several exciting—although not yet perfect—multifocal intraocular lenses (IOLs) for presbyopia correction from which to choose. Currently in the United States, the recently approved ...
San Diego, Ca, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center, leads the forefront of vision technology in San Diego with their newest Intraocular ...
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) has surpassed more than one million ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results